Follow-up: weeks 6 and 9 Daily iv. infusions of Cerebrolysin 50 ml or placebo for 21 days in patients hospitalized within 6 h after TBI End point: no GCS and CGI differences; faster GCS (p = 0.007 ...
NIDRR awards TBI Model Systems grants to institutions that are national leaders in medical research and patient care; these institutions provide the highest level of comprehensive specialty services ...
About AL01211 AL01211 is a proprietary, non-brain-penetrant GCS inhibitor with high potency (single-digit nanomolar IC50), excellent selectivity, and favorable drug properties that support once ...
Follow-up: weeks 6 and 9 Daily iv. infusions of Cerebrolysin 50 ml or placebo for 21 days in patients hospitalized within 6 h after TBI End point: no GCS and CGI differences; faster GCS (p = 0.007 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback